Abstract: A surgical treatment apparatus includes a first unit including a first vibration transmission member and a first holding member, a second unit including a second vibration transmission member, a second holding member, and an elastic member provided between the second vibration transmission member and the second holding member, configured to be deformed in accordance with a relative arrangement of the second vibration transmission member and the second holding member with respect to the axial direction to give the second vibration transmission member an elastic force in the axial direction, and an adjustment coupling mechanism to couple the first unit and the second unit with each other, arrange the first vibration transmission member and the second vibration transmission member coaxially to abut the end portion of the first vibration transmission member and the end portion of the second vibration transmission member against each other, and adjust a relative arrangement of the first holding member and the seco

Abstract: An ultrasonic wave vibrating apparatus includes a passive element converting electric energy to ultrasonic vibration, electrodes, a horn body arranged in a forward side of the element and amplifying the vibration, a backing arranged in the base side of the element and backing the element, and a horn connecting portion having one end connected to the body and the other end connected to the backing to connect the body and the backing to each other with the element sandwiched between the body and the backing. At least one of the body, the connecting portion and the backing is formed of metallic glass. The body and the connecting portion can be formed of the metallic glass integrally with each other. A cover covering the element may be included, and the cover, the body and the connecting portion can be formed of the metallic glass integrally with each other.

Abstract: An ultrasonic transmission member including one end part and the other end part and transmitting an ultrasonic wave input into the one end part to the other end part is formed by preparing a main mold having a casting cavity corresponding to a whole outer shape of the ultrasonic transmission member, melting an alloy which is a material of a metallic glass, and pouring the melted alloy into the casting cavity of the main mold to solidify the melted alloy in a liquid phase state thereof.

Abstract: A liquid crystal display device constrains the injection of air bubbles in a cooling fluid into a display panel. In the display device, the cooling fluid is supplied to a receiving space of a receiving unit placed and opposed to a surface of a liquid crystal panel to which the light is emitted from a light source to thereby cool the liquid crystal panel. Namely, by a cooling fluid pump, the cooling fluid received in the receiving unit is drained from a drain port and the cooling fluid is supplied from a feed port to the receiving unit and received in the receiving space. In the above case, a part of a flow path of the cooling fluid supplied from the feed port is blocked by a flow path block unit placed and opposed to the feed port to thereby disperse the flow thereof around the flow path block unit.

Abstract: The present invention provides therapeutic agents for sensory disorders represented by the following formula (1): [wherein R1, R2, and R3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. The cyclohexenone long chain alcohol of the present invention improves hyperalgesia or hypoalgesia, and thus is useful as therapeutic agents for sensory disorders. Sensory disorders that can be prevented or treated by the present invention include chronic intractable pain, neurogenic pain, reduction of pain threshold caused by nerve injuries, hypesthesia or hyperesthesia caused by diabetes and nerve injuries, and the like.

Abstract: The present invention provides compounds represented by formula (1) shown below: (wherein R1, R2, R3, R4, and R5 are each individually selected from among a hydrogen atom, methyl group, acetyl group, hydroxyl group, and alkoxy group; and X represents an alkylene group or alkenylene group); and compounds represented by formula (2) shown below: (wherein R6, R7, R8, R9, and R10 are each individually selected from among a hydrogen atom, alkyl group, acetyl group, hydroxyl group, and alkoxy group; A represents an oxygen atom or NH, and m is 0 or 1; and Y represents an alkylene group or alkenylene group, and Z represents a hydrogen atom or hydroxyl group). The compounds of the present invention are useful for preventing or treating brain dysfunctions, motor dysfunctions, or urinary dysfunctions caused by the degeneration and/or loss of the central nervous system or peripheral nervous system cells.

Abstract: The present invention provides preventive and/or therapeutic agents for either one, or both, of a diabetic vascular disorder and a diabetic respiratory disorder comprising, as an active ingredient, a cyclohexenone long chain alcohol compound represented by the following formula (1): [wherein R1, R2, and R3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. Since the cyclohexenone long chain alcohol of formula (1) improves diabetic vascular smooth muscle contraction and bronchial smooth muscle contraction, it is useful as a preventive and/or therapeutic agent for a diabetic vascular disorder or a respiratory disorder.

Abstract: Provided is an indole long-chain alcohol, or a hydrate or an isomer thereof, represented by the following formula (I): wherein R1, R2, R3 and R4 each independently represent a hydrogen atom, a methyl group, an acetyl group, or a hydroxyl group, and n represents a number from 0 to 20; and a medicinal composition comprising the same. The indole long-chain alcohol (I) exhibits an excellent nerve growth promoting effect, as well as potent antioxidative and anti-tumor effects, and is therefore useful as a prophylactic and/or therapeutic agent for cerebral diseases including dementia diseases, and malignant tumors including brain tumors.

Abstract: A data signal to be transmitted is supplied to a modulator of a transmitter, and the modulator modulates the output of a blue light-excited white LED and outputs blue LED light and phosphor light. The modulated blue light enters to a photo-electric converter through an LED light transmission color filter. The modulated phosphor light on the other hand enters to another photo-electric converter through a phosphor light transmission color filter. The photo-electric converters convert incident light to electric signals. The converted signals are amplified by amplifiers. Then, equalizers emphasize the harmonic component therein according to the response characteristic of the blue light and the response characteristic of the phosphor light for reduction of the dullness of waveforms.

Abstract: An ultrasonic treatment apparatus includes an ultrasonic transducer to generate ultrasonic vibration, a probe a proximal end of which is connected to the ultrasonic transducer and which extends from a proximal end side to a distal end side, and a treatment portion which includes at least one recess formed on the side of the probe and treats a living tissue by ultrasonic vibration generated by the ultrasonic transducer.

Abstract: Provided is an indole long-chain alcohol, or a hydrate or an isomer thereof, represented by the following formula (I): wherein R1, R2, R3 and R4 each independently represent a hydrogen atom, a methyl group, an acetyl group, or a hydroxyl group, and n represents a number from 0 to 20; and a medicinal composition comprising the same. The indole long-chain alcohol (I) exhibits an excellent nerve growth promoting effect, as well as potent antioxidative and anti-tumor effects, and is therefore useful as a prophylactic and/or therapeutic agent for cerebral diseases including dementia diseases, and malignant tumors including brain tumors.

Abstract: A protein introduction method with which protein can be introduced into cells with excellent safety is provided. A target protein is supported on a carrier for protein introduction that is made from a clay mineral, and by adding this to cells it is possible to introduce the target protein into the cells. The clay mineral is preferably a layered clay mineral, and as the clay mineral it is possible to use montmorillonite, vermiculite, and illite, for example.

Abstract: The objective of the present invention is to identify compounds having an inhibitory effect on adipocyte differentiation, and to provide pharmaceutical compositions and food compositions for prevention, improvement, or treatment of obesity or obesity related diseases. By enthusiastically studying natural products that inhibit the differentiation induction of adipocyte precursors into adipocytes, sesquiterpenoid derivatives, which are extracts from a Compositae plant, Calea, growing in Central and South America, were demonstrated to have an excellent inhibitory effect on adipocyte differentiation induction. Calea extract or the sesquiterpenoid derivatives are expected to be used in pharmaceutical compositions and food compositions for prevention, improvement, or treatment of obesity or obesity related diseases.

Abstract: The objective of the present invention is to identify compounds having an inhibitory effect on adipocyte differentiation, and to provide pharmaceutical compositions and food compositions for prevention, improvement, or treatment of obesity or obesity related diseases. By enthusiastically studying natural products that inhibit the differentiation induction of adipocyte precursors into adipocytes, sesquiterpenoid derivatives, which are extracts from a Compositae plant, Calea, growing in Central and South America, were demonstrated to have an excellent inhibitory effect on adipocyte differentiation induction. Calea extract or the sesquiterpenoid derivatives are expected to be used in pharmaceutical compositions and food compositions for prevention, improvement, or treatment of obesity related diseases.

Abstract: The present invention relates to an agent for improving renal dysfunction comprising as an active ingredient a compound represented by the following formula (1): wherein each R1, R2, and R3 represents a hydrogen atom or a methyl group, and X represents a linear or branched alkylene or alkenylene group having 10 to 28 carbon atoms.

Abstract: A liquid crystal display for use in a LCD projector includes a liquid crystal display panel including a TFT substrate, a counter substrate, and liquid crystal interposed between the TFT substrate and the counter substrate; a flexible film substrate being electrically coupled to the liquid crystal display panel and having a plurality of leads including at least one dummy lead; and a driving IC for driving the liquid crystal display panel, the driving IC being disposed on the film substrate and having at least one dummy bump. The dummy bump is connected to the dummy lead, and the dummy lead has a heat releasing function.

Abstract: An indole derivative represented by the following general formula (1): wherein at least one of R1, R2, R3, and R4 represents an alkoxy group containing 1 to 20 carbon atoms, and other groups of the R1, R2, R3, and R4 represent hydrogen, an alkyl group containing 1 to 6 carbon atoms, acetyl group, or hydroxyl group; and either one of X and Y represents —(CH2)nOH wherein n is an integer of 0 to 30, and the other one of the X and Y represents hydrogen atom; or a salt thereof; and a drug and an agent for promoting differentiation of a stem cell containing such indole derivative or its salt as an effective component, wherein the indole derivative (1) has action of inducing differentiation of neural stem cell specifically into a neuron, and this indole derivative is useful as a prophylactic or therapeutic drug for brain dysfunction or neuropathy caused by loss or degeneration of the neuron.

Abstract: A process for producing cyclohexenone long-chain alcohol represented by the following formula (1): (wherein A represents a C10-C18 alkylene or alkenylene group, and each of R1, R2, and R3 individually represents hydrogen or methyl), comprising reacting a 3-alkoxy-2-cyclohexen-1-one derivative represented by the following formula (2): (wherein R1, R2, and R3 have the same meanings as above, and R4 represents a C1-C5 alkyl group) with a Grignard's reagent prepared by protecting the hydroxyl groups of C10-C18 ?-halogenoalcohol through silylation, and hydrolyzing the resultant reaction product.

Abstract: The present invention provides a TNF-? production inhibitor containing a kavalactone as an active ingredient, which inhibitor has high safety, exerts an excellent effect of inhibiting TNF-? production, and is useful as a drug or an animal drug for preventing, ameliorating, or treating diseases such as cachexia attributed to cancer or infectious diseases, chronic rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus (SLE), rejection during bone marrow transplantation, multiple organ failure, AIDS, meningitis, hepatitis, and type-II diabetes. The present invention also provides a preventive, ameliorating, or therapeutic agent for diseases caused by abnormal production of TNF-?, the agent containing a kavalactone as an active ingredient.

Abstract: Provided is a medicament having an excellent therapeutic effect on ageing macular degeneration. The therapeutic agent for ageing macular degeneration comprises a progesterone derivative represented by the following formula (1): (wherein, R1 represents an alkyl group having from 1 to 23 carbon atoms) as an effective ingredient.